COMPREHENSIVE ASSESSMENT OF COMBORIDITY IN CLINICAL PRACTICE: METHODICAL APPROACHES AND PRACTICAL USE
Aim: to evaluate current approaches to the assessment of comorbidity in clinical practice and determine the prevalence of comorbidities in patients with coronary artery disease (CAD) who underwent coronary artery stenting. Material and methods. We performed a retrospective analysis of data from el...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
G.Z. Moroz [verfasserIn] I.M. Hidzynska [verfasserIn] T.S. Lasytsia [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch ; Russisch ; Ukrainisch |
| Erschienen: |
2021 |
|---|
| Schlagwörter: |
comorbidity, charlson comorbidity index, coronary artery disease |
|---|
| Übergeordnetes Werk: |
In: Клінічна та профілактична медицина - State Institution of Science «Research and Practical Center of Preventive and Clinical Medicine» State Administrative Department, 2020, (2021), 2, Seite 32-38 |
|---|---|
| Übergeordnetes Werk: |
year:2021 ; number:2 ; pages:32-38 |
| Links: |
|---|
| DOI / URN: |
10.31612/2616-4868.2(16).2021.04 |
|---|
| Katalog-ID: |
DOAJ053023935 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ053023935 | ||
| 003 | DE-627 | ||
| 005 | 20240412225839.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230227s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.31612/2616-4868.2(16).2021.04 |2 doi | |
| 035 | |a (DE-627)DOAJ053023935 | ||
| 035 | |a (DE-599)DOAJ2e205dfbb0804c499686dadf8fa22210 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng |a rus |a ukr | ||
| 100 | 0 | |a G.Z. Moroz |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COMPREHENSIVE ASSESSMENT OF COMBORIDITY IN CLINICAL PRACTICE: METHODICAL APPROACHES AND PRACTICAL USE |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Aim: to evaluate current approaches to the assessment of comorbidity in clinical practice and determine the prevalence of comorbidities in patients with coronary artery disease (CAD) who underwent coronary artery stenting. Material and methods. We performed a retrospective analysis of data from electronic medical records of 150 CAD patients below 75 yrs having undergone myocardial revascularization via percutaneous coronary intervention (coronary artery stenting). All of them were under the monitoring of the cardiologists of the State Institution of Science «Research and Practical Center of Preventive and Clinical Medicine” State Administrative Department. Comorbidity assessment was performed via diseases count; we have dealt only with diseases that are included in the Charlson Comorbidity Index (ССІ) and Combined Age Charlson Comorbidity Index (СА-ССІ) calculation proceeding. We used statistical software programs (Statistica v. 6.0) and Microsoft Excel 2007 applications for data analysis. Results. According to data of the medical records the most common comorbidities (among those used to calculate CCI and CA-CCI) in patients with CAD below 75 yrs who underwent coronary artery stenting were cerebrovascular disease (83.3 ± 3.0%), peripheral vascular diseases (42,7±4,0%), type 2 diabetes mellitus, and mild liver diseases (24,0±3,6%). It was found that the number of comorbid diseases in patients having been examined ranged from 2 to 7, with an average of 3,9±0,1. The mean number of diseases in patients of different ages did not differ significantly. The average CA-CCI value increased from 4,4±0,2 points in patients who had two diseases to 12,7±1,1 points in those with seven ones (р<0,05). Conclusions. Our study revealed a high prevalence of comorbidities in patients with CAD below 75 yrs who underwent coronary artery stenting. The use of CA-CCI allowed making a comprehensive assessment of patient’s conditions | ||
| 650 | 4 | |a comorbidity, charlson comorbidity index, coronary artery disease | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 700 | 0 | |a I.M. Hidzynska |e verfasserin |4 aut | |
| 700 | 0 | |a T.S. Lasytsia |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Клінічна та профілактична медицина |d State Institution of Science «Research and Practical Center of Preventive and Clinical Medicine» State Administrative Department, 2020 |g (2021), 2, Seite 32-38 |w (DE-627)1760608238 |x 26164868 |7 nnns |
| 773 | 1 | 8 | |g year:2021 |g number:2 |g pages:32-38 |
| 856 | 4 | 0 | |u https://doi.org/10.31612/2616-4868.2(16).2021.04 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/2e205dfbb0804c499686dadf8fa22210 |z kostenfrei |
| 856 | 4 | 0 | |u https://cp-medical.com/index.php/journal/article/view/160 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2616-4868 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |j 2021 |e 2 |h 32-38 | ||
| author_variant |
g m gm i h ih t l tl |
|---|---|
| matchkey_str |
article:26164868:2021----::opeesvassmnocmoiiynlnclrcieehdclp |
| hierarchy_sort_str |
2021 |
| publishDate |
2021 |
| allfields |
10.31612/2616-4868.2(16).2021.04 doi (DE-627)DOAJ053023935 (DE-599)DOAJ2e205dfbb0804c499686dadf8fa22210 DE-627 ger DE-627 rakwb eng rus ukr G.Z. Moroz verfasserin aut COMPREHENSIVE ASSESSMENT OF COMBORIDITY IN CLINICAL PRACTICE: METHODICAL APPROACHES AND PRACTICAL USE 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Aim: to evaluate current approaches to the assessment of comorbidity in clinical practice and determine the prevalence of comorbidities in patients with coronary artery disease (CAD) who underwent coronary artery stenting. Material and methods. We performed a retrospective analysis of data from electronic medical records of 150 CAD patients below 75 yrs having undergone myocardial revascularization via percutaneous coronary intervention (coronary artery stenting). All of them were under the monitoring of the cardiologists of the State Institution of Science «Research and Practical Center of Preventive and Clinical Medicine” State Administrative Department. Comorbidity assessment was performed via diseases count; we have dealt only with diseases that are included in the Charlson Comorbidity Index (ССІ) and Combined Age Charlson Comorbidity Index (СА-ССІ) calculation proceeding. We used statistical software programs (Statistica v. 6.0) and Microsoft Excel 2007 applications for data analysis. Results. According to data of the medical records the most common comorbidities (among those used to calculate CCI and CA-CCI) in patients with CAD below 75 yrs who underwent coronary artery stenting were cerebrovascular disease (83.3 ± 3.0%), peripheral vascular diseases (42,7±4,0%), type 2 diabetes mellitus, and mild liver diseases (24,0±3,6%). It was found that the number of comorbid diseases in patients having been examined ranged from 2 to 7, with an average of 3,9±0,1. The mean number of diseases in patients of different ages did not differ significantly. The average CA-CCI value increased from 4,4±0,2 points in patients who had two diseases to 12,7±1,1 points in those with seven ones (р<0,05). Conclusions. Our study revealed a high prevalence of comorbidities in patients with CAD below 75 yrs who underwent coronary artery stenting. The use of CA-CCI allowed making a comprehensive assessment of patient’s conditions comorbidity, charlson comorbidity index, coronary artery disease Medicine R I.M. Hidzynska verfasserin aut T.S. Lasytsia verfasserin aut In Клінічна та профілактична медицина State Institution of Science «Research and Practical Center of Preventive and Clinical Medicine» State Administrative Department, 2020 (2021), 2, Seite 32-38 (DE-627)1760608238 26164868 nnns year:2021 number:2 pages:32-38 https://doi.org/10.31612/2616-4868.2(16).2021.04 kostenfrei https://doaj.org/article/2e205dfbb0804c499686dadf8fa22210 kostenfrei https://cp-medical.com/index.php/journal/article/view/160 kostenfrei https://doaj.org/toc/2616-4868 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 2021 2 32-38 |
| spelling |
10.31612/2616-4868.2(16).2021.04 doi (DE-627)DOAJ053023935 (DE-599)DOAJ2e205dfbb0804c499686dadf8fa22210 DE-627 ger DE-627 rakwb eng rus ukr G.Z. Moroz verfasserin aut COMPREHENSIVE ASSESSMENT OF COMBORIDITY IN CLINICAL PRACTICE: METHODICAL APPROACHES AND PRACTICAL USE 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Aim: to evaluate current approaches to the assessment of comorbidity in clinical practice and determine the prevalence of comorbidities in patients with coronary artery disease (CAD) who underwent coronary artery stenting. Material and methods. We performed a retrospective analysis of data from electronic medical records of 150 CAD patients below 75 yrs having undergone myocardial revascularization via percutaneous coronary intervention (coronary artery stenting). All of them were under the monitoring of the cardiologists of the State Institution of Science «Research and Practical Center of Preventive and Clinical Medicine” State Administrative Department. Comorbidity assessment was performed via diseases count; we have dealt only with diseases that are included in the Charlson Comorbidity Index (ССІ) and Combined Age Charlson Comorbidity Index (СА-ССІ) calculation proceeding. We used statistical software programs (Statistica v. 6.0) and Microsoft Excel 2007 applications for data analysis. Results. According to data of the medical records the most common comorbidities (among those used to calculate CCI and CA-CCI) in patients with CAD below 75 yrs who underwent coronary artery stenting were cerebrovascular disease (83.3 ± 3.0%), peripheral vascular diseases (42,7±4,0%), type 2 diabetes mellitus, and mild liver diseases (24,0±3,6%). It was found that the number of comorbid diseases in patients having been examined ranged from 2 to 7, with an average of 3,9±0,1. The mean number of diseases in patients of different ages did not differ significantly. The average CA-CCI value increased from 4,4±0,2 points in patients who had two diseases to 12,7±1,1 points in those with seven ones (р<0,05). Conclusions. Our study revealed a high prevalence of comorbidities in patients with CAD below 75 yrs who underwent coronary artery stenting. The use of CA-CCI allowed making a comprehensive assessment of patient’s conditions comorbidity, charlson comorbidity index, coronary artery disease Medicine R I.M. Hidzynska verfasserin aut T.S. Lasytsia verfasserin aut In Клінічна та профілактична медицина State Institution of Science «Research and Practical Center of Preventive and Clinical Medicine» State Administrative Department, 2020 (2021), 2, Seite 32-38 (DE-627)1760608238 26164868 nnns year:2021 number:2 pages:32-38 https://doi.org/10.31612/2616-4868.2(16).2021.04 kostenfrei https://doaj.org/article/2e205dfbb0804c499686dadf8fa22210 kostenfrei https://cp-medical.com/index.php/journal/article/view/160 kostenfrei https://doaj.org/toc/2616-4868 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 2021 2 32-38 |
| allfields_unstemmed |
10.31612/2616-4868.2(16).2021.04 doi (DE-627)DOAJ053023935 (DE-599)DOAJ2e205dfbb0804c499686dadf8fa22210 DE-627 ger DE-627 rakwb eng rus ukr G.Z. Moroz verfasserin aut COMPREHENSIVE ASSESSMENT OF COMBORIDITY IN CLINICAL PRACTICE: METHODICAL APPROACHES AND PRACTICAL USE 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Aim: to evaluate current approaches to the assessment of comorbidity in clinical practice and determine the prevalence of comorbidities in patients with coronary artery disease (CAD) who underwent coronary artery stenting. Material and methods. We performed a retrospective analysis of data from electronic medical records of 150 CAD patients below 75 yrs having undergone myocardial revascularization via percutaneous coronary intervention (coronary artery stenting). All of them were under the monitoring of the cardiologists of the State Institution of Science «Research and Practical Center of Preventive and Clinical Medicine” State Administrative Department. Comorbidity assessment was performed via diseases count; we have dealt only with diseases that are included in the Charlson Comorbidity Index (ССІ) and Combined Age Charlson Comorbidity Index (СА-ССІ) calculation proceeding. We used statistical software programs (Statistica v. 6.0) and Microsoft Excel 2007 applications for data analysis. Results. According to data of the medical records the most common comorbidities (among those used to calculate CCI and CA-CCI) in patients with CAD below 75 yrs who underwent coronary artery stenting were cerebrovascular disease (83.3 ± 3.0%), peripheral vascular diseases (42,7±4,0%), type 2 diabetes mellitus, and mild liver diseases (24,0±3,6%). It was found that the number of comorbid diseases in patients having been examined ranged from 2 to 7, with an average of 3,9±0,1. The mean number of diseases in patients of different ages did not differ significantly. The average CA-CCI value increased from 4,4±0,2 points in patients who had two diseases to 12,7±1,1 points in those with seven ones (р<0,05). Conclusions. Our study revealed a high prevalence of comorbidities in patients with CAD below 75 yrs who underwent coronary artery stenting. The use of CA-CCI allowed making a comprehensive assessment of patient’s conditions comorbidity, charlson comorbidity index, coronary artery disease Medicine R I.M. Hidzynska verfasserin aut T.S. Lasytsia verfasserin aut In Клінічна та профілактична медицина State Institution of Science «Research and Practical Center of Preventive and Clinical Medicine» State Administrative Department, 2020 (2021), 2, Seite 32-38 (DE-627)1760608238 26164868 nnns year:2021 number:2 pages:32-38 https://doi.org/10.31612/2616-4868.2(16).2021.04 kostenfrei https://doaj.org/article/2e205dfbb0804c499686dadf8fa22210 kostenfrei https://cp-medical.com/index.php/journal/article/view/160 kostenfrei https://doaj.org/toc/2616-4868 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 2021 2 32-38 |
| allfieldsGer |
10.31612/2616-4868.2(16).2021.04 doi (DE-627)DOAJ053023935 (DE-599)DOAJ2e205dfbb0804c499686dadf8fa22210 DE-627 ger DE-627 rakwb eng rus ukr G.Z. Moroz verfasserin aut COMPREHENSIVE ASSESSMENT OF COMBORIDITY IN CLINICAL PRACTICE: METHODICAL APPROACHES AND PRACTICAL USE 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Aim: to evaluate current approaches to the assessment of comorbidity in clinical practice and determine the prevalence of comorbidities in patients with coronary artery disease (CAD) who underwent coronary artery stenting. Material and methods. We performed a retrospective analysis of data from electronic medical records of 150 CAD patients below 75 yrs having undergone myocardial revascularization via percutaneous coronary intervention (coronary artery stenting). All of them were under the monitoring of the cardiologists of the State Institution of Science «Research and Practical Center of Preventive and Clinical Medicine” State Administrative Department. Comorbidity assessment was performed via diseases count; we have dealt only with diseases that are included in the Charlson Comorbidity Index (ССІ) and Combined Age Charlson Comorbidity Index (СА-ССІ) calculation proceeding. We used statistical software programs (Statistica v. 6.0) and Microsoft Excel 2007 applications for data analysis. Results. According to data of the medical records the most common comorbidities (among those used to calculate CCI and CA-CCI) in patients with CAD below 75 yrs who underwent coronary artery stenting were cerebrovascular disease (83.3 ± 3.0%), peripheral vascular diseases (42,7±4,0%), type 2 diabetes mellitus, and mild liver diseases (24,0±3,6%). It was found that the number of comorbid diseases in patients having been examined ranged from 2 to 7, with an average of 3,9±0,1. The mean number of diseases in patients of different ages did not differ significantly. The average CA-CCI value increased from 4,4±0,2 points in patients who had two diseases to 12,7±1,1 points in those with seven ones (р<0,05). Conclusions. Our study revealed a high prevalence of comorbidities in patients with CAD below 75 yrs who underwent coronary artery stenting. The use of CA-CCI allowed making a comprehensive assessment of patient’s conditions comorbidity, charlson comorbidity index, coronary artery disease Medicine R I.M. Hidzynska verfasserin aut T.S. Lasytsia verfasserin aut In Клінічна та профілактична медицина State Institution of Science «Research and Practical Center of Preventive and Clinical Medicine» State Administrative Department, 2020 (2021), 2, Seite 32-38 (DE-627)1760608238 26164868 nnns year:2021 number:2 pages:32-38 https://doi.org/10.31612/2616-4868.2(16).2021.04 kostenfrei https://doaj.org/article/2e205dfbb0804c499686dadf8fa22210 kostenfrei https://cp-medical.com/index.php/journal/article/view/160 kostenfrei https://doaj.org/toc/2616-4868 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 2021 2 32-38 |
| allfieldsSound |
10.31612/2616-4868.2(16).2021.04 doi (DE-627)DOAJ053023935 (DE-599)DOAJ2e205dfbb0804c499686dadf8fa22210 DE-627 ger DE-627 rakwb eng rus ukr G.Z. Moroz verfasserin aut COMPREHENSIVE ASSESSMENT OF COMBORIDITY IN CLINICAL PRACTICE: METHODICAL APPROACHES AND PRACTICAL USE 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Aim: to evaluate current approaches to the assessment of comorbidity in clinical practice and determine the prevalence of comorbidities in patients with coronary artery disease (CAD) who underwent coronary artery stenting. Material and methods. We performed a retrospective analysis of data from electronic medical records of 150 CAD patients below 75 yrs having undergone myocardial revascularization via percutaneous coronary intervention (coronary artery stenting). All of them were under the monitoring of the cardiologists of the State Institution of Science «Research and Practical Center of Preventive and Clinical Medicine” State Administrative Department. Comorbidity assessment was performed via diseases count; we have dealt only with diseases that are included in the Charlson Comorbidity Index (ССІ) and Combined Age Charlson Comorbidity Index (СА-ССІ) calculation proceeding. We used statistical software programs (Statistica v. 6.0) and Microsoft Excel 2007 applications for data analysis. Results. According to data of the medical records the most common comorbidities (among those used to calculate CCI and CA-CCI) in patients with CAD below 75 yrs who underwent coronary artery stenting were cerebrovascular disease (83.3 ± 3.0%), peripheral vascular diseases (42,7±4,0%), type 2 diabetes mellitus, and mild liver diseases (24,0±3,6%). It was found that the number of comorbid diseases in patients having been examined ranged from 2 to 7, with an average of 3,9±0,1. The mean number of diseases in patients of different ages did not differ significantly. The average CA-CCI value increased from 4,4±0,2 points in patients who had two diseases to 12,7±1,1 points in those with seven ones (р<0,05). Conclusions. Our study revealed a high prevalence of comorbidities in patients with CAD below 75 yrs who underwent coronary artery stenting. The use of CA-CCI allowed making a comprehensive assessment of patient’s conditions comorbidity, charlson comorbidity index, coronary artery disease Medicine R I.M. Hidzynska verfasserin aut T.S. Lasytsia verfasserin aut In Клінічна та профілактична медицина State Institution of Science «Research and Practical Center of Preventive and Clinical Medicine» State Administrative Department, 2020 (2021), 2, Seite 32-38 (DE-627)1760608238 26164868 nnns year:2021 number:2 pages:32-38 https://doi.org/10.31612/2616-4868.2(16).2021.04 kostenfrei https://doaj.org/article/2e205dfbb0804c499686dadf8fa22210 kostenfrei https://cp-medical.com/index.php/journal/article/view/160 kostenfrei https://doaj.org/toc/2616-4868 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 2021 2 32-38 |
| language |
English Russian Ukrainian |
| source |
In Клінічна та профілактична медицина (2021), 2, Seite 32-38 year:2021 number:2 pages:32-38 |
| sourceStr |
In Клінічна та профілактична медицина (2021), 2, Seite 32-38 year:2021 number:2 pages:32-38 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
comorbidity, charlson comorbidity index, coronary artery disease Medicine R |
| isfreeaccess_bool |
true |
| container_title |
Клінічна та профілактична медицина |
| authorswithroles_txt_mv |
G.Z. Moroz @@aut@@ I.M. Hidzynska @@aut@@ T.S. Lasytsia @@aut@@ |
| publishDateDaySort_date |
2021-01-01T00:00:00Z |
| hierarchy_top_id |
1760608238 |
| id |
DOAJ053023935 |
| language_de |
englisch russisch ukrainisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ053023935</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240412225839.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.31612/2616-4868.2(16).2021.04</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ053023935</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ2e205dfbb0804c499686dadf8fa22210</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield><subfield code="a">rus</subfield><subfield code="a">ukr</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">G.Z. Moroz</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">COMPREHENSIVE ASSESSMENT OF COMBORIDITY IN CLINICAL PRACTICE: METHODICAL APPROACHES AND PRACTICAL USE</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Aim: to evaluate current approaches to the assessment of comorbidity in clinical practice and determine the prevalence of comorbidities in patients with coronary artery disease (CAD) who underwent coronary artery stenting. Material and methods. We performed a retrospective analysis of data from electronic medical records of 150 CAD patients below 75 yrs having undergone myocardial revascularization via percutaneous coronary intervention (coronary artery stenting). All of them were under the monitoring of the cardiologists of the State Institution of Science «Research and Practical Center of Preventive and Clinical Medicine” State Administrative Department. Comorbidity assessment was performed via diseases count; we have dealt only with diseases that are included in the Charlson Comorbidity Index (ССІ) and Combined Age Charlson Comorbidity Index (СА-ССІ) calculation proceeding. We used statistical software programs (Statistica v. 6.0) and Microsoft Excel 2007 applications for data analysis. Results. According to data of the medical records the most common comorbidities (among those used to calculate CCI and CA-CCI) in patients with CAD below 75 yrs who underwent coronary artery stenting were cerebrovascular disease (83.3 ± 3.0%), peripheral vascular diseases (42,7±4,0%), type 2 diabetes mellitus, and mild liver diseases (24,0±3,6%). It was found that the number of comorbid diseases in patients having been examined ranged from 2 to 7, with an average of 3,9±0,1. The mean number of diseases in patients of different ages did not differ significantly. The average CA-CCI value increased from 4,4±0,2 points in patients who had two diseases to 12,7±1,1 points in those with seven ones (р<0,05). Conclusions. Our study revealed a high prevalence of comorbidities in patients with CAD below 75 yrs who underwent coronary artery stenting. The use of CA-CCI allowed making a comprehensive assessment of patient’s conditions</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">comorbidity, charlson comorbidity index, coronary artery disease</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">I.M. Hidzynska</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">T.S. Lasytsia</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Клінічна та профілактична медицина</subfield><subfield code="d">State Institution of Science «Research and Practical Center of Preventive and Clinical Medicine» State Administrative Department, 2020</subfield><subfield code="g">(2021), 2, Seite 32-38</subfield><subfield code="w">(DE-627)1760608238</subfield><subfield code="x">26164868</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">year:2021</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:32-38</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.31612/2616-4868.2(16).2021.04</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/2e205dfbb0804c499686dadf8fa22210</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://cp-medical.com/index.php/journal/article/view/160</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2616-4868</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="j">2021</subfield><subfield code="e">2</subfield><subfield code="h">32-38</subfield></datafield></record></collection>
|
| author |
G.Z. Moroz |
| spellingShingle |
G.Z. Moroz misc comorbidity, charlson comorbidity index, coronary artery disease misc Medicine misc R COMPREHENSIVE ASSESSMENT OF COMBORIDITY IN CLINICAL PRACTICE: METHODICAL APPROACHES AND PRACTICAL USE |
| authorStr |
G.Z. Moroz |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)1760608238 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut |
| collection |
DOAJ |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
26164868 |
| topic_title |
COMPREHENSIVE ASSESSMENT OF COMBORIDITY IN CLINICAL PRACTICE: METHODICAL APPROACHES AND PRACTICAL USE comorbidity, charlson comorbidity index, coronary artery disease |
| topic |
misc comorbidity, charlson comorbidity index, coronary artery disease misc Medicine misc R |
| topic_unstemmed |
misc comorbidity, charlson comorbidity index, coronary artery disease misc Medicine misc R |
| topic_browse |
misc comorbidity, charlson comorbidity index, coronary artery disease misc Medicine misc R |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Клінічна та профілактична медицина |
| hierarchy_parent_id |
1760608238 |
| hierarchy_top_title |
Клінічна та профілактична медицина |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)1760608238 |
| title |
COMPREHENSIVE ASSESSMENT OF COMBORIDITY IN CLINICAL PRACTICE: METHODICAL APPROACHES AND PRACTICAL USE |
| ctrlnum |
(DE-627)DOAJ053023935 (DE-599)DOAJ2e205dfbb0804c499686dadf8fa22210 |
| title_full |
COMPREHENSIVE ASSESSMENT OF COMBORIDITY IN CLINICAL PRACTICE: METHODICAL APPROACHES AND PRACTICAL USE |
| author_sort |
G.Z. Moroz |
| journal |
Клінічна та профілактична медицина |
| journalStr |
Клінічна та профілактична медицина |
| lang_code |
eng rus ukr |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2021 |
| contenttype_str_mv |
txt |
| container_start_page |
32 |
| author_browse |
G.Z. Moroz I.M. Hidzynska T.S. Lasytsia |
| format_se |
Elektronische Aufsätze |
| author-letter |
G.Z. Moroz |
| doi_str_mv |
10.31612/2616-4868.2(16).2021.04 |
| author2-role |
verfasserin |
| title_sort |
comprehensive assessment of comboridity in clinical practice: methodical approaches and practical use |
| title_auth |
COMPREHENSIVE ASSESSMENT OF COMBORIDITY IN CLINICAL PRACTICE: METHODICAL APPROACHES AND PRACTICAL USE |
| abstract |
Aim: to evaluate current approaches to the assessment of comorbidity in clinical practice and determine the prevalence of comorbidities in patients with coronary artery disease (CAD) who underwent coronary artery stenting. Material and methods. We performed a retrospective analysis of data from electronic medical records of 150 CAD patients below 75 yrs having undergone myocardial revascularization via percutaneous coronary intervention (coronary artery stenting). All of them were under the monitoring of the cardiologists of the State Institution of Science «Research and Practical Center of Preventive and Clinical Medicine” State Administrative Department. Comorbidity assessment was performed via diseases count; we have dealt only with diseases that are included in the Charlson Comorbidity Index (ССІ) and Combined Age Charlson Comorbidity Index (СА-ССІ) calculation proceeding. We used statistical software programs (Statistica v. 6.0) and Microsoft Excel 2007 applications for data analysis. Results. According to data of the medical records the most common comorbidities (among those used to calculate CCI and CA-CCI) in patients with CAD below 75 yrs who underwent coronary artery stenting were cerebrovascular disease (83.3 ± 3.0%), peripheral vascular diseases (42,7±4,0%), type 2 diabetes mellitus, and mild liver diseases (24,0±3,6%). It was found that the number of comorbid diseases in patients having been examined ranged from 2 to 7, with an average of 3,9±0,1. The mean number of diseases in patients of different ages did not differ significantly. The average CA-CCI value increased from 4,4±0,2 points in patients who had two diseases to 12,7±1,1 points in those with seven ones (р<0,05). Conclusions. Our study revealed a high prevalence of comorbidities in patients with CAD below 75 yrs who underwent coronary artery stenting. The use of CA-CCI allowed making a comprehensive assessment of patient’s conditions |
| abstractGer |
Aim: to evaluate current approaches to the assessment of comorbidity in clinical practice and determine the prevalence of comorbidities in patients with coronary artery disease (CAD) who underwent coronary artery stenting. Material and methods. We performed a retrospective analysis of data from electronic medical records of 150 CAD patients below 75 yrs having undergone myocardial revascularization via percutaneous coronary intervention (coronary artery stenting). All of them were under the monitoring of the cardiologists of the State Institution of Science «Research and Practical Center of Preventive and Clinical Medicine” State Administrative Department. Comorbidity assessment was performed via diseases count; we have dealt only with diseases that are included in the Charlson Comorbidity Index (ССІ) and Combined Age Charlson Comorbidity Index (СА-ССІ) calculation proceeding. We used statistical software programs (Statistica v. 6.0) and Microsoft Excel 2007 applications for data analysis. Results. According to data of the medical records the most common comorbidities (among those used to calculate CCI and CA-CCI) in patients with CAD below 75 yrs who underwent coronary artery stenting were cerebrovascular disease (83.3 ± 3.0%), peripheral vascular diseases (42,7±4,0%), type 2 diabetes mellitus, and mild liver diseases (24,0±3,6%). It was found that the number of comorbid diseases in patients having been examined ranged from 2 to 7, with an average of 3,9±0,1. The mean number of diseases in patients of different ages did not differ significantly. The average CA-CCI value increased from 4,4±0,2 points in patients who had two diseases to 12,7±1,1 points in those with seven ones (р<0,05). Conclusions. Our study revealed a high prevalence of comorbidities in patients with CAD below 75 yrs who underwent coronary artery stenting. The use of CA-CCI allowed making a comprehensive assessment of patient’s conditions |
| abstract_unstemmed |
Aim: to evaluate current approaches to the assessment of comorbidity in clinical practice and determine the prevalence of comorbidities in patients with coronary artery disease (CAD) who underwent coronary artery stenting. Material and methods. We performed a retrospective analysis of data from electronic medical records of 150 CAD patients below 75 yrs having undergone myocardial revascularization via percutaneous coronary intervention (coronary artery stenting). All of them were under the monitoring of the cardiologists of the State Institution of Science «Research and Practical Center of Preventive and Clinical Medicine” State Administrative Department. Comorbidity assessment was performed via diseases count; we have dealt only with diseases that are included in the Charlson Comorbidity Index (ССІ) and Combined Age Charlson Comorbidity Index (СА-ССІ) calculation proceeding. We used statistical software programs (Statistica v. 6.0) and Microsoft Excel 2007 applications for data analysis. Results. According to data of the medical records the most common comorbidities (among those used to calculate CCI and CA-CCI) in patients with CAD below 75 yrs who underwent coronary artery stenting were cerebrovascular disease (83.3 ± 3.0%), peripheral vascular diseases (42,7±4,0%), type 2 diabetes mellitus, and mild liver diseases (24,0±3,6%). It was found that the number of comorbid diseases in patients having been examined ranged from 2 to 7, with an average of 3,9±0,1. The mean number of diseases in patients of different ages did not differ significantly. The average CA-CCI value increased from 4,4±0,2 points in patients who had two diseases to 12,7±1,1 points in those with seven ones (р<0,05). Conclusions. Our study revealed a high prevalence of comorbidities in patients with CAD below 75 yrs who underwent coronary artery stenting. The use of CA-CCI allowed making a comprehensive assessment of patient’s conditions |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ |
| container_issue |
2 |
| title_short |
COMPREHENSIVE ASSESSMENT OF COMBORIDITY IN CLINICAL PRACTICE: METHODICAL APPROACHES AND PRACTICAL USE |
| url |
https://doi.org/10.31612/2616-4868.2(16).2021.04 https://doaj.org/article/2e205dfbb0804c499686dadf8fa22210 https://cp-medical.com/index.php/journal/article/view/160 https://doaj.org/toc/2616-4868 |
| remote_bool |
true |
| author2 |
I.M. Hidzynska T.S. Lasytsia |
| author2Str |
I.M. Hidzynska T.S. Lasytsia |
| ppnlink |
1760608238 |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.31612/2616-4868.2(16).2021.04 |
| up_date |
2024-07-03T15:22:02.650Z |
| _version_ |
1803571820130992128 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ053023935</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240412225839.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.31612/2616-4868.2(16).2021.04</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ053023935</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ2e205dfbb0804c499686dadf8fa22210</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield><subfield code="a">rus</subfield><subfield code="a">ukr</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">G.Z. Moroz</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">COMPREHENSIVE ASSESSMENT OF COMBORIDITY IN CLINICAL PRACTICE: METHODICAL APPROACHES AND PRACTICAL USE</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Aim: to evaluate current approaches to the assessment of comorbidity in clinical practice and determine the prevalence of comorbidities in patients with coronary artery disease (CAD) who underwent coronary artery stenting. Material and methods. We performed a retrospective analysis of data from electronic medical records of 150 CAD patients below 75 yrs having undergone myocardial revascularization via percutaneous coronary intervention (coronary artery stenting). All of them were under the monitoring of the cardiologists of the State Institution of Science «Research and Practical Center of Preventive and Clinical Medicine” State Administrative Department. Comorbidity assessment was performed via diseases count; we have dealt only with diseases that are included in the Charlson Comorbidity Index (ССІ) and Combined Age Charlson Comorbidity Index (СА-ССІ) calculation proceeding. We used statistical software programs (Statistica v. 6.0) and Microsoft Excel 2007 applications for data analysis. Results. According to data of the medical records the most common comorbidities (among those used to calculate CCI and CA-CCI) in patients with CAD below 75 yrs who underwent coronary artery stenting were cerebrovascular disease (83.3 ± 3.0%), peripheral vascular diseases (42,7±4,0%), type 2 diabetes mellitus, and mild liver diseases (24,0±3,6%). It was found that the number of comorbid diseases in patients having been examined ranged from 2 to 7, with an average of 3,9±0,1. The mean number of diseases in patients of different ages did not differ significantly. The average CA-CCI value increased from 4,4±0,2 points in patients who had two diseases to 12,7±1,1 points in those with seven ones (р<0,05). Conclusions. Our study revealed a high prevalence of comorbidities in patients with CAD below 75 yrs who underwent coronary artery stenting. The use of CA-CCI allowed making a comprehensive assessment of patient’s conditions</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">comorbidity, charlson comorbidity index, coronary artery disease</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">I.M. Hidzynska</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">T.S. Lasytsia</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Клінічна та профілактична медицина</subfield><subfield code="d">State Institution of Science «Research and Practical Center of Preventive and Clinical Medicine» State Administrative Department, 2020</subfield><subfield code="g">(2021), 2, Seite 32-38</subfield><subfield code="w">(DE-627)1760608238</subfield><subfield code="x">26164868</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">year:2021</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:32-38</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.31612/2616-4868.2(16).2021.04</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/2e205dfbb0804c499686dadf8fa22210</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://cp-medical.com/index.php/journal/article/view/160</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2616-4868</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="j">2021</subfield><subfield code="e">2</subfield><subfield code="h">32-38</subfield></datafield></record></collection>
|
| score |
7.398777 |